California State Teachers Retirement System Has $7.41 Billion Stock Holdings in Medpace Holdings, Inc. $MEDP

California State Teachers Retirement System raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 53,619.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,989,649 shares of the company's stock after purchasing an additional 13,963,607 shares during the period. California State Teachers Retirement System owned approximately 50.12% of Medpace worth $7,408,778,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Johnson Financial Group Inc. bought a new stake in Medpace during the second quarter worth $27,000. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new position in shares of Medpace in the 4th quarter valued at $30,000. Jones Financial Companies Lllp acquired a new position in shares of Medpace during the 2nd quarter worth $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter worth $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medpace news, CEO August Troendle sold 27,174 shares of Medpace stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the transaction, the chief executive officer directly owned 561,195 shares of the company's stock, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Fred Davenport, Jr. sold 7,283 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 134,471 shares of company stock valued at $82,151,311 over the last 90 days. 20.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Robert W. Baird boosted their target price on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research note on Friday, July 24th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, Mizuho increased their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $595.20.

Medpace Stock Performance

MEDP stock opened at $590.89 on Wednesday. The company has a fifty day moving average price of $577.04 and a 200-day moving average price of $502.19. The company has a market capitalization of $16.49 billion, a P/E ratio of 34.64, a PEG ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.